Kingdon Capital Management, L.L.C. Fate Therapeutics Inc Transaction History

Kingdon Capital Management, L.L.C.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 14, 2018	SELL	$3.94 - $6.64 $1.53 Million - $2.57 Million	-387,294 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $1.01 Million - $1.67 Million	387,294	387,294 $1.53 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.